MARKET

NVRO

NVRO

Nevro
NYSE

Real-time Quotes | Nasdaq Last Sale

147.08
+1.33
+0.91%
After Hours: 147.08 0 0.00% 16:00 04/09 EDT
OPEN
146.18
PREV CLOSE
145.75
HIGH
147.41
LOW
144.99
VOLUME
188.88K
TURNOVER
--
52 WEEK HIGH
188.14
52 WEEK LOW
101.90
MARKET CAP
5.09B
P/E (TTM)
-59.1395
1D
5D
1M
3M
1Y
5Y
US Electroceuticals Market Share 2019: Trends, Key Players, Industry Analysis and Report 2019-2025
Apr 09, 2021 (Market Insight Reports) -- US electroceuticals market is expected to grow at a CAGR of 7.8% during the forecast period. The market growth is...
Market Insight Reports · 2d ago
Spinal Cord Stimulation Devices Market To Power And Cross USD 3.60 Bn By 2028
Apr 09, 2021 (Market Stats News via COMTEX) -- The global Spinal Cord Stimulation Devices market To Power And Cross USD 3.60 Bn By 2028, according to a new...
Market Stats News · 2d ago
Electrotherapy Market Share, Growth Rate, Trends and Forecast 2027
ABNewswire · 2d ago
Global Electroceuticals Medicine Market Growth, Status and Outlook Research Report 2021-2026
Heraldkeepers · 3d ago
Nevro to Report First Quarter 2021 Financial Results
, /PRNewswire/ -- Nevro Corp. (NYSE: NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that the company will report its financial results for the first quarter ...
PR Newswire - PRF · 4d ago
Neurostimulation Devices Market 2024 | Overview and scope, Industry Outlook, Size & Forecast
Apr 06, 2021 (AmericaNewsHour) -- Global Neurostimulation devices Market is estimated to reach $10.2 Billion by 2024; growing at a CAGR of 12.7% from 2016 to...
AmericaNewsHour · 5d ago
Neurostimulation Devices Market Technology, Product Scope, Demand, Business Scenario, Trends, Share, Applications, Types and Forecasts 2020 - 2027
Market Insight Reports · 5d ago
Nevro Announces Publication Of Landmark SENZA-PDN Clinical Trial Results In JAMA Neurology
Nevro Corp. (NYSE:NVRO), a global medical device company that is providing innovative, evidence-based solutions for the treatment of chronic pain, today announced that results of its SENZA-PDN randomized
Benzinga · 6d ago
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of NVRO. Analyze the recent business situations of Nevro through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 16 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average NVRO stock price target is 199.50 with a high estimate of 217.00 and a low estimate of 170.00.
EPS
Institutional Holdings
Institutions: 318
Institutional Holdings: 42.47M
% Owned: 122.67%
Shares Outstanding: 34.62M
TypeInstitutionsShares
Increased
84
1.81M
New
47
1.54M
Decreased
69
2.42M
Sold Out
31
350.11K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Medical Equipment, Supplies & Distribution
+1.13%
Healthcare Equipment & Supplies
+1.08%
Key Executives
Chairman/President/Chief Executive Officer/Director
D.Keith Grossman
Chief Financial Officer
Roderick MacLeod
Chief Human Resource Officer
Lori Ciano
Chief Compliance Officer/General Counsel/Secretary
Kashif Rashid
Vice President - Operations
Patrick Schmitz
Vice President/Director of Sales
Michael Carter
Vice President/Director of Investor Relations/IR Contact Officer
Juliet Cunningham
Vice President/Director of Investor Relations
Julie Dewey
Vice President
Donald Middlebrook
Vice President - Research & Development
Christopher Christoforou
Other
David Caraway
Other
Niamh Pellegrini
Lead Director/Independent Director
Michael DeMane
Director
Susan Siegel
Independent Director
Frank Fischer
Independent Director
Shawn McCormick
Independent Director
Kevin O'Boyle
Independent Director
Karen Prange
Independent Director
Brad Vale
Independent Director
Elizabeth Weatherman
No Data
  • All
  • Financials
  • Insiders
More
About NVRO
Nevro Corp. is a global medical device company. The Company focuses on providing products that improve the quality of life of patients suffering from chronic pain. The Company has developed and commercialized the Senza spinal cord stimulation (SCS) system, an evidence-based neuromodulation platform for the treatment of chronic pain. Its HF10 therapy is designed to deliver neuromodulation solutions for treating chronic pain. HF10 therapy enables patients to achieve sustained pain relief without paresthesia, thus enabling its patients to avoid the uncomfortable shocking or jolting sensations commonly associated with paresthesia. HF10 therapy relies on consistent anatomical lead placement. As of December 31, 2016, it was investigating the use of HF10 therapy to address additional indications, such as chronic upper limb and neck pain, painful neuropathies and non-surgical refractory back pain. The Senza system is approved to create electrical impulses from 2 hertz (Hz) to 10,000 Hz.

Webull offers kinds of Nevro Corp stock information, including NYSE:NVRO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, NVRO stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading NVRO stock methods without spending real money on the virtual paper trading platform.